R. Alpert

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

V. Bedian, J. Gardner, T. Paradis, 2011, Cancer Immunology, Immunotherapy.

trans-3-Benzyl-4-hydroxy-7-chromanylbenzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor.

B. Dominy, M. Ramchandani, M. Conklyn, 1998, Bioorganic & medicinal chemistry letters.

The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.

M. Smith, A. Milici, E. Pettipher, 1998, The Journal of pharmacology and experimental therapeutics.

PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases

Douglas Burdette, A. Milici, H. Runnels, 2010, Advances in therapy.

IDENTIFICATION OF A HISTAMINE H4 RECEPTOR ON HUMAN EOSINOPHILS—ROLE IN EOSINOPHIL CHEMOTAXIS

M. Trevethick, M. Fidock, S. Trim, 2002, Journal of receptor and signal transduction research.

In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells, and chemotherapy.

V. Bedian, T. Paradis, R. Gladue, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases

Douglas Burdette, A. Milici, H. Runnels, 2010, Advances in therapy.